Analyst Ratings — November 12, 2026 — Midday Update — Last 24 Hours (Pacific Time)

Executive Summary

The dominant story of the past 24 hours is an unprecedented wave of Nvidia downgrades and price target cuts following reports surrounding CEO Jensen Huang — at least six firms downgraded or slashed targets, making it the most consequential single-stock event of the session. Beyond Nvidia, analyst sentiment was broadly mixed-to-constructive, with notable upgrades in steel, real estate storage, and pharma, while crypto-adjacent names and select energy stocks faced target reductions. Cantor Fitzgerald, H.C. Wainwright, Stifel, and Raymond James were the most active firms across the board.

Analyst Action Breakdown

Net Sentiment: Mixed — PT raises and cuts are nearly balanced, but the high-profile Nvidia downgrade wave and several other notable cuts (EVgo, Janus International, Reddit, CoreWeave) weigh on sentiment. Upgrades in steel, AMD, and MDU Resources provide some bullish offset, but downgrades outnumber upgrades roughly 1.5:1.

Top Analyst Calls

🔴 Multiple Firms → Nvidia (NVDA) — Downgraded/PT Cut (Wave)

• KeyBanc: Downgraded to Sector Weight from Overweight, removed PT — CEO succession concerns
• Melius: Downgraded to Hold from Buy, cut PT to $185 from $315 — CEO departure uncertainty
• Bernstein: Downgraded to Market Perform from Outperform, cut PT — CEO uncertainty
• Oppenheimer: Downgraded to Perform from Outperform, removed PT — CEO departure reports
• Evercore ISI: Downgraded to In Line from Outperform, cut PT — CEO uncertainty
• William Blair: Downgraded to Market Perform from Outperform — CEO uncertainty
• BMO: Maintained Outperform but cut PT to $240 from $340 — CEO governance concerns
• RBC: Maintained Outperform but cut PT to $230 from $330 — CEO investigation uncertainty
• Stifel: Maintained Buy but cut PT to $205 from $315 — leadership uncertainty
• StoneX: Downgraded to Hold from Buy, suspended $335 PT — CEO departure
• Goldman Sachs: Maintained Buy, kept $220 PT — reiterated conviction post-departure
• Raymond James: Maintained Strong Buy, kept $515 PT — reiterated despite CEO transition
• Piper Sandler: Maintained Overweight, kept $300 PT — reiterated amid CEO uncertainty
• Baird: Maintained Neutral, kept $200 PT — no change post-resignation
• Rationale: Reports of CEO Jensen Huang's departure triggered the broadest single-stock analyst reaction of the session.

🟢 William Blair → AMD (AMD) — Upgraded to Outperform from Market Perform

• Rationale: Data center strength across all four business segments drove the upgrade.

🟢 Barclays → Reliance Steel (RS) — Upgraded to Overweight from Equalweight, PT Raised

• Rationale: Border wall contract win seen as a significant near-term revenue catalyst.

🟢 Barclays → Cleveland-Cliffs (CLF) — Upgraded to Equalweight from Underweight

• Rationale: Improving steel prices drove the rating upgrade.

🔴 Stifel → EVgo (EVGO) — Downgraded to Hold from Buy, PT Cut to $2.50 from $6.00

• Rationale: Go-private bid and slower-than-expected EV charging growth prompted the sharp cut.

🟢 Piper Sandler → Teva Pharmaceutical (TEVA) — PT Raised to $56 from $44, maintains Overweight

• Rationale: Pipeline strength seen as a significant underappreciated value driver.

🟢 Rosenblatt → Atlanta Braves (BATRK) — PT Raised to $91 from $73, maintains Buy

• Rationale: Upward revision to team valuation underpins the significant target increase.

🔴 Argus → Reddit (RDDT) — PT Cut to $150 from $225, maintains Buy

• Rationale: Search-related concerns weigh on the growth outlook despite maintained Buy.

🔴 Argus → CoreWeave — PT Cut to $100 from $150, maintains Buy

• Rationale: Debt concerns prompted a significant target reduction on the cloud AI name.

🟢 Truist → Public Storage (PSA) — PT Raised to $365 from $317, maintains Buy

• Rationale: Pricing gains driving improved fundamentals in the self-storage sector.

🟢 Truist → Extra Space Storage (EXR) — PT Raised to $172 from $147, maintains Buy

• Rationale: Improving fundamentals across the self-storage segment.

🟢 DA Davidson → Riskified (RSKD) — PT Raised to $12 from $9, maintains Buy

• Rationale: Strong results drove the target increase; Truist also raised to $14 from $9.

🔴 Morgan Stanley → Teleperformance (TLPFY) — Downgraded to Underweight from Equalweight

• Rationale: Automation risks seen as a structural threat to the business model.

🟢 Jefferies → Jones Lang LaSalle (JLL) — PT Raised to $438 from $372, maintains Buy

• Rationale: Leasing activity rebound driving a significant upward revision.

🔴 StoneX → Janus International (JBI) — PT Cut to $5 from $9, maintains Buy

• Rationale: Weak Q3 results drove a steep 44% target reduction.

Firm Activity Summary

H.C. Wainwright — 14 calls (13 bullish, 0 bearish, 1 neutral)

• Buys reiterated: Monopar (MNPR), Quantum-Si (QSI), Compugen (CGEN), Janux (JANX), Integra Resources (ITRG), Alpha Cognition (ACOG), Harmony Bio (HRMY), Madrigal (MDGL), Amprius (AMPX), Alto Neuroscience (ANRO), Teva (TEVA)
• Initiations (Buy): Worksport (WKSP), Savara (SVRA)

Stifel — 11 calls (9 bullish, 1 bearish, 1 neutral)

• Buys reiterated/maintained: AtriCure (ATRC), MaxCyte (MXCT), Legence (LGN), Palo Alto Networks (PANW), Rivian (RIVN)
• PT cuts (maintains Buy): OptimizeRx (OPRX), Applied Aerospace, Alcon (ALC — Hold)
• Downgrade: EVgo (EVGO) to Hold
• Nvidia (NVDA): Maintains Buy, cuts PT

Raymond James — 11 calls (10 bullish, 0 bearish, 1 neutral)

• Strong Buy reiterations: Nvidia (NVDA), Aveanna (AVHH), Globe Life (GL), Skyward Specialty (SKWD), Allstate (ALL), Uniti Group (UNIT)
• Outperform reiterations: Yeti (YETI), Engene (ENGN), Evommune (EVMN)
• PT raise: Alpha Cognition (ACOG)
• Upgrade: Mid Penn Bancorp (MPB) to Strong Buy
• Market Perform reiteration: Edgewell (EPC)

Cantor Fitzgerald — 8 calls (5 bullish, 1 bearish, 2 neutral)

• Overweight reiterations: Anteris Technologies, Lexeo Therapeutics (LXEO), Coinbase (COIN)
• PT raise: Exodus Movement (EXOD) to $16 from $15
• PT cuts: eToro (ETOR) to $37 from $48, Coincheck (CNCK) to $1.80 from $2.50
• Neutral reiteration: Merck (MRK)

Jefferies — 10 calls (7 bullish, 0 bearish, 3 neutral)

• Buys reiterated: SOLV Energy (MWH), Teva (TEVA), Core & Main (CNM), Alcon (ALC), Boot Barn (BOOT)
• PT raises: Cushman & Wakefield (CWK) to $14, Jones Lang LaSalle (JLL) to $438
• Upgrade: Pattern Group (PTRN) to Buy
• Holds reiterated: Franco Nevada (FNV), Capri Holdings (CPRI), Chagee Holdings (CHA)

BTIG — 9 calls (7 bullish, 1 bearish, 1 neutral)

• Buys reiterated: Monopar (MNPR), Live Nation (LYV), PennyMac Financial (PFSI), Delcath Systems (DCTH), Amer Sports (AS)
• PT raise: NRx Pharmaceuticals (NRXP) to $12 from $10
• PT cut: T1 Energy (TE) to $7 from $9 (maintains Buy), EnerSys (ENS) to $250 from $280, BrightView (BV) to $12 from $15
• Initiation (Buy): Quantinuum (QNT)

Truist Securities — 8 calls (6 bullish, 1 bearish, 1 neutral)

• PT raises: Extra Space Storage (EXR), Public Storage (PSA), Riskified (RSKD), Shift4 Payments (FOUR), Oddity Tech (ODD)
• PT cut: FIS to $31 from prior
• Holds: ADI Global Distribution (ADIG), Cardinal Infrastructure (CDNL — Buy reiteration)

StoneX — 8 calls (6 bullish, 1 bearish, 1 neutral)

• Buys reiterated: Humacyte (HUMA), Exodus Movement (EXOD), Bakkt (BKKT), A2Z Smart Technology (AZ), Patrick Industries (PATK)
• PT raise: Unity Software to $56 from $50
• PT cut: Janus International (JBI) to $5 from $9
• Downgrade: Nvidia (NVDA) to Hold
• Hold reiteration: Bio-Techne (TECH)

DA Davidson — 8 calls (5 bullish, 0 bearish, 3 neutral)

• PT raises: Riskified (RSKD) to $12, Grocery Outlet (GO) to $14, Emerson Electric (EMR) to $160
• PT cut: Kennametal (KMT) to $25 from $30 (Neutral)
• Buys reiterated: EVI Industries (EVI), Guardian Metal Resources (GMTL)
• Neutrals reiterated: Advance Auto Parts (AAP) x2

Bernstein SocGen — 6 calls (2 bullish, 1 bearish, 3 neutral)

• Outperform reiterations: Sea Ltd. (SE), Apple (AAPL)
• Market Perform reiterations: Pfizer (PFE), Revvity (RVTY)
• PT cut: Alcon (ALC) to $88.90 from $92.35
• Downgrade: Nvidia (NVDA) to Market Perform

Argus — 6 calls (5 bullish, 1 bearish)

• PT raises: Gilead (GILD) to $190, Vivmark Residential (VMRK) to $72, Amgen (AMGN) to $515, Wayfair (W) to $135, Cardinal Health (CAH) to $309
• PT cut: Reddit (RDDT) to $150 from $225, CoreWeave to $100 from $150

Piper Sandler — 6 calls (4 bullish, 1 bearish, 1 neutral)

• PT raises: Teva (TEVA) to $56, Jazz Pharmaceuticals (JAZZ) to $330
• PT cut: Cigna to $360 from $370, Digi International (DGII) to $67 from $76
• Overweight reiterations: Jack Henry (JKHY), Valvoline (VVV), Nvidia (NVDA)

BMO Capital — 5 calls (4 bullish, 0 bearish, 1 neutral)

• PT raises: Array Technologies (ARRY) to $7, CGI Group (GIB) to Cdn$132, Global-E Online (GLBE) to $51
• PT cut: Nvidia (NVDA) to $240 from $340 (maintains Outperform)
• Outperform reiteration: NIQ Global (NIQ)

Wedbush — 5 calls (2 bullish, 1 bearish, 2 neutral)

• PT raises: Burford Capital (BUR) to $3.25, DoubleDown Interactive (DDI) to $16.25
• Underperform reiteration: Eikon Therapeutics (EIKN)
• Neutral reiterations: Terrestrial Energy (IMSR), CI&T (CINT), Moonlake (MLTX — Outperform)

Citizens — 7 calls (6 bullish, 0 bearish, 1 neutral)

• Market Outperform reiterations: Kura Oncology (KURA), Spruce Biosciences (SPRU), MBX Biosciences (MBX), M/I Homes (MHO), Galaxy Digital (GLXY), EZCORP (EZPW)
• PT raise: Resideo Technologies (REZI) to $29 from $22

Barclays — 4 calls (3 bullish, 0 bearish, 1 neutral)

• Upgrades: Cleveland-Cliffs (CLF) to Equalweight, Reliance Steel (RS) to Overweight
• Initiations: Dorman Products (DORM — Overweight), Cars.com (CARS — Equalweight)

BofA Securities — 5 calls (2 bullish, 3 bearish)

• PT raises: Teekay Tankers (TNK) to $83, Royal Caribbean (RCL) to $365
• Buy reiteration: Nokia (NOK)
• Downgrades: Victoria's Secret (VSCO) to Neutral, iHeartMedia (IHRT) to Underperform, Suja Life (SUJA) to Underperform
• PT cut: Fervo Energy (FRVO) to $25 from $30

JPMorgan — 3 calls (1 bullish, 1 bearish, 1 neutral)

• Upgrade: Alamtri Resources Indonesia (ADOOY) to Overweight
• Downgrade: Innoviz Technologies (INVZ) to Neutral
• Initiation: Agility Robotics (AGLT) at Neutral

Morgan Stanley — 4 calls (2 bullish, 1 bearish, 1 neutral)

• PT raises: Royal Caribbean (RCL) to $330, Applied Aerospace (AADX) to $17, JFrog (FROG) to $114
• PT cut: ITG (ITG) to $9 from $18 (maintains Equalweight)
• Downgrade: Teleperformance (TLPFY) to Underweight

Mizuho — 4 calls (2 bullish, 1 bearish, 1 neutral)

• Outperform reiterations: Affirm (AFRM), Corteva (CTVA)
• PT cuts: Boyd Group (BGSI) to $115 from $120, Corbus Pharmaceuticals (CRBP) to $23 from $24

KeyBanc — 5 calls (1 bullish, 1 bearish, 3 neutral)

• Downgrade: Nvidia (NVDA) to Sector Weight
• Upgrade: Maravai LifeSciences (MRVI) to Overweight
• Underweight reiteration: Apple (AAPL)
• PT cuts: ITG (ITG) to $10, Flex (FLEX) to $128 from $180
• Sector Weight reiteration: Mosaic (MOS)

Sector Trends

Technology & AI — Nvidia Dominates, AMD Gains: The Nvidia CEO situation created a bifurcated tech narrative. At least six firms downgraded NVDA outright while others slashed targets by 30–40%, reflecting genuine governance uncertainty rather than fundamental business concerns. Notably, Goldman Sachs and Raymond James held firm with bullish ratings, creating a rare and wide analyst divergence on a mega-cap name. The flip side: William Blair upgraded AMD to Outperform on data center strength, suggesting capital rotation within semiconductors may be on analysts' minds.

Real Estate & Storage — Quietly Bullish: Self-storage REITs saw meaningful upgrades, with Truist raising Public Storage's target to $365 from $317 and Extra Space Storage to $172 from $147 — both citing improving fundamentals and pricing power. Commercial real estate also saw constructive moves, with Jefferies raising Jones Lang LaSalle's target to $438 from $372 and Cushman & Wakefield to $14 from $13 on a capital markets rebound.

Pharma & Biotech — Pipeline Optimism Drives Raises: Multiple firms raised targets on pharmaceutical names, with Piper Sandler lifting Teva to $56 from $44, Argus raising Amgen to $515 and Gilead to $190, and Jazz Pharmaceuticals getting a bump to $330 from $310. H.C. Wainwright was broadly constructive across its biotech coverage. On the downside, Alcon received cuts from both Bernstein and Stifel on Q3 revenue misses and 2027 growth concerns, representing a notable consensus softening on the eye-care name.

Market Implications

The Nvidia situation is the clearest signal for investors: when six or more firms downgrade a mega-cap in a single session, the market is pricing in genuine uncertainty — not just a temporary dip. The divergence between firms like Goldman Sachs and Raymond James (holding Strong Buy) versus Melius, Bernstein, and Oppenheimer (downgrading) suggests the investment community is genuinely split on whether CEO succession risk is transient or structural. Investors holding NVDA face a rare moment of analyst consensus breakdown, which historically increases volatility regardless of direction.

Sector rotation signals are emerging. The AMD upgrade from William Blair, combined with broad Nvidia weakness, hints at analysts beginning to redistribute semiconductor conviction. Meanwhile, the dual Truist upgrades on self-storage REITs and multiple pharma target raises suggest defensive and healthcare positioning is gaining favor among analysts — a pattern worth watching as a potential risk-off signal.

The crypto-adjacent space is seeing mixed signals: Cantor cut eToro and Coincheck targets while maintaining bullish ratings, and Susquehanna also trimmed eToro — suggesting lower volatility is compressing revenue expectations for trading platforms even as underlying crypto sentiment remains constructive. The steel sector stands out as a rare clean upgrade story, with Barclays lifting both Cleveland-Cliffs and Reliance Steel on steel prices and contract wins.

Key Takeaways

• 🔴 Nvidia (NVDA) — Six firms downgraded in one session on CEO uncertainty; targets range from $185 (Melius) to $515 (Raymond James), an unprecedented divergence on a mega-cap.
• 🟢 AMD (AMD) — William Blair upgraded to Outperform on data center strength, potentially the key beneficiary of Nvidia uncertainty.
• 🔴 EVgo (EVGO) — Stifel cut to Hold and slashed PT to $2.50 from $6.00 on go-private bid and slower EV growth — a 58% target reduction.
• 🟢 Reliance Steel (RS) — Barclays upgraded to Overweight on a border wall contract win, a concrete near-term catalyst.
• 🟢 Teva Pharmaceutical (TEVA) — Piper Sandler raised PT to $56 from $44; multiple firms bullish on pipeline strength.
• 🔴 Janus International (JBI) — StoneX cut PT to $5 from $9 (44% reduction) on weak Q3 results.
• 🔴 Reddit (RDDT) — Argus cut PT to $150 from $225 (33% reduction) on search-related concerns, despite maintaining Buy.
• 🔴 CoreWeave — Argus cut PT to $100 from $150 on debt concerns, a 33% reduction.
• 🟢 Public Storage (PSA) — Truist raised PT to $365 from $317; self-storage sector broadly constructive.
• 🟢 Jones Lang LaSalle (JLL) — Jefferies raised PT to $438 from $372 on leasing rebound — commercial real estate showing signs of life.
• 🔴 Alcon (ALC) — Both Bernstein and Stifel cut targets on Q3 miss and 2027 growth concerns; Jefferies holds Buy at $85.
• 🔴 Teleperformance (TLPFY) — Morgan Stanley downgraded to Underweight on automation risks — a structural bear thesis.
• 🟢 Riskified (RSKD) — Both DA Davidson (to $12) and Truist (to $14) raised targets on strong results — rare dual-firm conviction.
• 🔴 eToro (ETOR) — Both Cantor (to $37 from $48) and Susquehanna (to $39 from $46) cut targets on lower volatility and trade volume declines.
• 🟢 Barclays initiates Dorman Products (DORM) at Overweight — new coverage with bullish conviction in auto parts.
• 🔴 iHeartMedia (IHRT) — BofA downgraded to Underperform on leverage concerns — a bearish structural call.
• 🟢 Mid Penn Bancorp (MPB) — Raymond James upgraded to Strong Buy from Outperform on growth outlook.
• 🔴 Flex (FLEX) — KeyBanc cut PT to $128 from $180 (29% reduction) on valuation update, maintains Overweight.
• 🟢 Royal Caribbean (RCL) — Both BofA (to $365) and Morgan Stanley (to $330) raised targets on demand and cost control.
• 🟢 Amgen (AMGN) — Argus raised PT to $515 on pipeline strength; part of a broad pharma upgrade wave.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

👉 This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/